These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 18794908)
1. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Bromley CM; Close S; Cohen N; Favis R; Fijal B; Gheyas F; Liu W; Lopez-Correa C; Prokop A; Singer JB; Snapir A; Tchelet A; Wang D; Goldstaub D; Pharmacogenomics J; 2009 Feb; 9(1):14-22. PubMed ID: 18794908 [TBL] [Abstract][Full Text] [Related]
2. Current practices for DNA sample collection and storage in the pharmaceutical industry, and potential areas for harmonization: perspective of the I-PWG. Franc MA; Warner AW; Cohen N; Shaw PM; Groenen P; Snapir A Clin Pharmacol Ther; 2011 Apr; 89(4):546-53. PubMed ID: 21368755 [TBL] [Abstract][Full Text] [Related]
3. Methodological quality of pharmacogenetic studies: issues of concern. Jorgensen AL; Williamson PR Stat Med; 2008 Dec; 27(30):6547-69. PubMed ID: 18837075 [TBL] [Abstract][Full Text] [Related]
4. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Anderson DC; Gomez-Mancilla B; Spear BB; Barnes DM; Cheeseman K; Shaw PM; Friedman J; McCarthy A; Brazell C; Ray SC; McHale D; Hashimoto L; Sandbrink R; Watson ML; Salerno RA; Cohen N; Lister CE; Pharmacogenomics J; 2002; 2(5):284-92. PubMed ID: 12439734 [No Abstract] [Full Text] [Related]
5. Coding of DNA samples and data in the pharmaceutical industry: current practices and future directions--perspective of the I-PWG. Franc MA; Cohen N; Warner AW; Shaw PM; Groenen P; Snapir A; Clin Pharmacol Ther; 2011 Apr; 89(4):537-45. PubMed ID: 21346752 [TBL] [Abstract][Full Text] [Related]
6. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Warner AW; Bhathena A; Gilardi S; Mohr D; Leong D; Bienfait KL; Sarang J; Duprey S; Franc MA; Nelsen A; Snapir A Clin Pharmacol Ther; 2011 Apr; 89(4):529-36. PubMed ID: 21346757 [TBL] [Abstract][Full Text] [Related]
7. Evolution of pharmacogenomics. Somogy A Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663 [TBL] [Abstract][Full Text] [Related]
8. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries. Ricci DS; Broderick ED; Tchelet A; Hong F; Mayevsky S; Mohr DM; Schaffer ME; Warner AW; Hakkulinen P; Snapir A Clin Pharmacol Ther; 2011 Apr; 89(4):554-61. PubMed ID: 21346753 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Serretti A; Kato M; Kennedy JL Pharmacogenomics J; 2008 Apr; 8(2):90-100. PubMed ID: 17684474 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics in drug discovery and development: a translational perspective. Roses AD Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics: from bench to byte. Swen JJ; Wilting I; de Goede AL; Grandia L; Mulder H; Touw DJ; de Boer A; Conemans JM; Egberts TC; Klungel OH; Koopmans R; van der Weide J; Wilffert B; Guchelaar HJ; Deneer VH Clin Pharmacol Ther; 2008 May; 83(5):781-7. PubMed ID: 18253145 [TBL] [Abstract][Full Text] [Related]
13. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Salerno RA; Lesko LJ Pharmacogenomics J; 2006; 6(2):78-81. PubMed ID: 16402087 [No Abstract] [Full Text] [Related]
14. The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Tremaine L; Brian W; DelMonte T; Francke S; Groenen P; Johnson K; Li L; Pearson K; Marshall JC Pharmacogenomics; 2015 Dec; 16(18):2055-67. PubMed ID: 26616152 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. Lesko LJ; Salerno RA; Spear BB; Anderson DC; Anderson T; Brazell C; Collins J; Dorner A; Essayan D; Gomez-Mancilla B; Hackett J; Huang SM; Ide S; Killinger J; Leighton J; Mansfield E; Meyer R; Ryan SG; Schmith V; Shaw P; Sistare F; Watson M; Worobec A J Clin Pharmacol; 2003 Apr; 43(4):342-58. PubMed ID: 12723455 [TBL] [Abstract][Full Text] [Related]
16. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Wang SJ Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727 [TBL] [Abstract][Full Text] [Related]
17. PhRMA survey of pharmacogenomic and pharmacodynamic evaluations: what next? Grecco N; Cohen N; Warner AW; Lopez-Correa C; Truter SL; Snapir A; Piccoli SP; Wang D; Westelinck A; Hinman L; Franc MA; Clin Pharmacol Ther; 2012 Jun; 91(6):1035-43. PubMed ID: 22534869 [TBL] [Abstract][Full Text] [Related]
18. Potential of adaptive clinical trial designs in pharmacogenetic research. van der Baan FH; Knol MJ; Klungel OH; Egberts AC; Grobbee DE; Roes KC Pharmacogenomics; 2012 Apr; 13(5):571-8. PubMed ID: 22462749 [TBL] [Abstract][Full Text] [Related]